Diverse functions of PLC enzymes in cancer could be mediated ... Taking as an example recent advances in therapeutics targeting the PI3K–Akt pathway, it is likely that targeting this alone ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

The Swiss drugmaker announced the global phase 3 SOLAR-1 trial evaluating the alpha-specific PI3K inhibitor codenamed BYL719 (alpelisib) has met the primary target and improved progression-free ...

The phosphoinositide 3-kinase (PI3K) pathway is a crucial signal transduction system linking the activation of receptor tyrosine kinases (RTKs), G protein-coupled receptors (GPCRs) and oncogenes ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...